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Background-—Even though clinical data support a relation between ischemic stroke and venous thromboembolism (VTE), the
strength and time dependence of the association remain to be settled at the population level. We therefore aimed to investigate
the association between ischemic stroke and VTE in a prospective population-based cohort.
Methods and Results-—Participants (n=30 002) were recruited from 3 surveys of the Tromsø study (conducted in 1994–1995,
2001, and 2007–2008) and followed through 2010. All incident events of ischemic stroke and VTE during follow-up were recorded.
Cox-regression models with age as time scale and ischemic stroke as a time-dependent variable were used to calculate hazard
ratios (HR) of VTE adjusted for cardiovascular risk factors. During a median follow-up time of 15.7 years, 1360 participants
developed ischemic stroke and 722 had a VTE. The risk of VTE was highest the ﬁrst month (HR 19.7; 95% CI, 10.1–38.5) and from
1 to 3 months after the stroke (HR 10.6; 95% CI 5.0–22.5), but declined rapidly thereafter. The risk estimates were approximately
the same for deep vein thrombosis (HR 19.1; 95% CI, 7.8–38.5), and pulmonary embolism (HR 20.2; 95% CI, 7.4–55.1). Stroke was
associated with higher risk for provoked (HR 22.6; 95% CI, 12.5–40.9) than unprovoked VTE (HR 7.4; 95% CI, 2.7–20.1) the ﬁrst
3 months.
Conclusions-—The risk of VTE increased during the ﬁrst 3 months after an ischemic stroke. The particularly high risk of provoked
VTE suggests that additional predisposing factors, such as immobilization, potentiate the VTE risk in patients with ischemic stroke.
( J Am Heart Assoc. 2016;5:e004311 doi: 10.1161/JAHA.116.004311)
Key Words: epidemiology • ischemic stroke • risk factor • venous thromboembolism
I schemic stroke is a major challenge to public health andhealthcare systems due to frequent hospitalizations,
frequent medical complications, disability, dependency, nurs-
ing home conﬁnement, and a high mortality rate.1–3 Even
though clinically overt pulmonary embolism (PE) occurs in
only 1% of stroke patients during the ﬁrst 14 days after an
acute stroke,4–6 PE may account for up to 25% to 50% of
deaths after acute stroke.6–8
Venous thromboembolism (VTE), a collective term for deep
vein thrombosis (DVT) and PE, is a common disease with
serious short- and long-term complications, such as develop-
ment of the post-thrombotic syndrome after a DVT, or death
due to circulatory collapse secondary to PE.9,10 VTE is a
multifactorial disease, and advancing age and obesity are
recognized as shared atherosclerotic risk factors for VTE and
ischemic stroke.11 In addition, immobilization, particularly in
an in-hospital setting, is associated with high risk of VTE.12–15
Therefore, neurological deﬁcits entailing immobilization and
other medical complications secondary to acute ischemic
stroke may predispose for VTE.2,16,17
Several randomized trials including selected patients with
acute ischemic stroke have assessed the risk of symptomatic
VTE in patients without and with antithrombotic treatment.4,5
Data from a meta-analysis displayed that the incidence of
asymptomatic and symptomatic DVT was 17% among 1186
patients with stroke, whereas the incidence of symptomatic
PE was 1.0% among 10 997 patients who did not receive
antithrombotic therapy during follow-up (controls).5 However,
limited data exist regarding the association between ischemic
From the K. G. Jebsen - Thrombosis Research and Expertise Center (TREC)
(L.B.R., B.S., E.B.M., I.N., E.M.H., S.K.B., J.-B.H.) and Brain and Circulation
Research Group (E.B.M.), Department of Clinical Medicine, and Epidemiology of
Chronic Diseases Research Group, Department of Community Medicine (M.-
L.L., I.N., T.W.), UiT The Arctic University of Norway, Tromsø, Norway; Division
of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
(E.M.H., S.K.B., J.-B.H.).
Correspondence to: Ludvig B. Rinde, BSc, Department of Clinical Medicine,
K. G. Jebsen - Thrombosis Research and Expertise Center (TREC), University of
Tromsø, The Arctic University of Norway, Tromsø N-9037, Norway. E-mail:
ludvig.b.rinde@uit.no
Received July 19, 2016; accepted September 27, 2016.
ª 2016 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs License, which
permits use and distribution in any medium, provided the original work is
properly cited, the use is non-commercial and no modiﬁcations or adaptations
are made.
DOI: 10.1161/JAHA.116.004311 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on June 18, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
stroke and risk of VTE in the general population. A registry-
based case–control study recruited from the general popula-
tion in Denmark revealed that patients with a history of stroke
had a short-term 4.4-fold increased risk of subsequent VTE
during the ﬁrst 3 months after stroke.18 Results from registry-
based studies should, however, be interpreted with caution
due to the lack of validation of exposure and outcomes and
inability to adjust for obvious confounders such as body mass
index (BMI).
The aim of the study was to investigate the overall and
time-dependent risk of VTE by ischemic stroke in a popula-
tion-based cohort with validated information on exposure
(ischemic stroke), end point (VTE), and potential confounders.
Methods
Study Population
The Tromsø Study is a single-center, prospective, population-
based study, with repeated health surveys of the inhabitants
of Tromsø, Norway. Study participants were recruited from
the fourth, ﬁfth, and sixth survey of the Tromsø Study,
conducted in 1994–1995, 2001, and 2007–2008, respec-
tively. The overall attendance rates were high: 77% in the
fourth, 78% in the ﬁfth, and 66% in the sixth survey. In total,
30 586 unique participants aged 25 to 97 years took part in
at least 1 of the surveys, and of these, 21 529 subjects
participated in 2 or all 3 surveys. Participants who did not
consent to medical research (n=225) and participants not
ofﬁcially registered as inhabitants of the municipality of
Tromsø at date of study enrollment (n=47) were excluded.
Furthermore, participants with a history of VTE (n=78) or
ischemic stroke (n=234) were excluded. Consequently,
30 002 participants were included in the study, and followed
from the date of enrollment to the end of follow-up, December
31, 2010 (Figure 1). The regional committee for medical and
health research ethics in North Norway approved the study,
and all participants gave their informed written consent.
Baseline Measurements
Information about the study participants was collected by
physical examinations, blood samples, and self-administered
questionnaires at each survey. Systolic and diastolic blood
pressures were measured 3 three times with 1-minute
intervals with an automatic device (Dinamap Vital Signs
Monitor, 1846; Critikon Inc, Tampa, FL) with participants in a
sitting position after 2 minutes of rest, and deﬁned as the
mean of the last 2 readings. Nonfasting blood samples were
collected from an antecubital vein, serum was prepared by
centrifugation after 1-hour respite at room temperature and
analyzed at the Department of Clinical Chemistry, University
Hospital of North Norway, Tromsø, Norway. Serum total
cholesterol was analyzed by an enzymatic colorimetric
method using a commercially available kit (CHOD-PAP;
Boehringer-Mannheim, Mannheim, Germany). Serum high-
density lipoprotein cholesterol was measured after precipita-
tion of lower-density lipoproteins with heparin and manganese
chloride. Height and weight were measured with participants
wearing light clothes and no shoes. BMI was calculated as
weight in kilograms divided by the square of height in meters
(kg/m2). Obesity (BMI ≥30 kg/m2) was classiﬁed according
to the World Health Organization deﬁnition.19 Hypertension
was classiﬁed as mean systolic blood pressure ≥140 mm Hg,
mean diastolic blood pressure ≥90 mm Hg, or self-reported
use of blood pressure–lowering drugs. Hypercholesterolemia
was classiﬁed as total serum cholesterol ≥6.5 mmol/L or
self-reported use of lipid-lowering drugs. Information on family
history of myocardial infarction, diabetes mellitus, physical
activity, and education level was collected from a self-
administered questionnaire.
Assessment of Ischemic Stroke
Ischemic stroke was deﬁned according to the World Health
Organization deﬁnition when computed tomography or mag-
netic resonance imaging scans or autopsy had ruled out brain
hemorrhage.20 An independent end-point committee
Figure 1. Inclusion of study participants from the fourth (1994–1995), ﬁfth (2001–2002),
and sixth (2007–2008) surveys of the Tromsø Study.
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performed validation of hospitalized and out-of-hospital
events of ischemic stroke based on data from hospital and
out-of-hospital journals, autopsy records, and death certiﬁ-
cates. The Norwegian national 11-digit identiﬁcation number
allowed linkage to national and local diagnosis registries.
Cases of possible incident ischemic stroke were identiﬁed by
linkage to the hospital discharge diagnosis registry at the
University Hospital of North Norway with a broad search for
the International Classiﬁcation of Diseases (ICD), 9th Revision
codes 430 to 438 in the period 1994 to 1998, and thereafter
for the ICD, 10th Revision codes I60 to I69. Manual and/or
electronic text searches were performed in paper versions
(used until 2001) and digital versions of hospital records for
notes on ischemic stroke in all participants with 1 or more of
these diagnoses for case validation.
Assessment of VTE
All incident VTE events during follow-up were identiﬁed by
searching the hospital discharge diagnosis registry, the
autopsy registry, and the radiology procedure registry at the
University Hospital of North Norway as previously
described.21 The University Hospital of North Norway is the
only hospital in the region, and all diagnostic radiology and
hospital care is provided exclusively by this hospital. The
medical record for each potential case of VTE was reviewed by
trained personnel, and a VTE event was considered veriﬁed
and recorded when presence of clinical signs and symptoms
of DVT or pulmonary embolism were combined with objective
conﬁrmation tests (by compression ultrasonography, venog-
raphy, spiral computed tomography, perfusion–ventilation
scan, pulmonary angiography, autopsy), and resulted in a
VTE diagnosis that required treatment, as previously
described in detail.21 VTE cases from the autopsy registry
were recorded when the death certiﬁcate indicated VTE as
cause of death or a signiﬁcant condition associated with
death. The VTE events were classiﬁed as provoked and
unprovoked, depending on the presence of provoking factors
at the time of diagnosis. Provoking factors were recent
surgery or trauma within the previous 8 weeks, acute medical
conditions (acute myocardial infarction, ischemic stroke, or
major infectious disease), active cancer, immobilization (bed
rest >3 days, wheelchair use, or long-distance travel exceed-
ing 4 hours within the last 14 days prior to the event) or any
other factors described by a physician in the medical record
(eg, intravascular catheter).
Statistical Analysis
Participants who developed ischemic stroke during the study
period contributed with nonexposed person-time from the
inclusion date to the date of a diagnosis of ischemic stroke,
and then with exposed person-time from the date of ischemic
stroke onwards. For each participant, nonexposed and
exposed person-years were counted from the date of
enrollment to the date of an incident diagnosis of VTE, the
date the participant died or moved from Tromsø, or until the
end of the study period, December 31, 2010, whichever came
ﬁrst. Participants who died or moved from the municipality
during follow-up were censored at the date of death or
migration.
Statistical analyses were performed using STATA version
14.0 (Stata Corporation, College Station, TX). Crude incidence
rates (IR) of VTE were calculated and expressed as number of
events per 1000 person-years at risk. Cox proportional
hazards regression models were used to calculate hazard
ratios (HR) with 95% CI of VTE, DVT, and PE after ischemic
stroke. Age was used as time scale in the Cox model, with the
age of the participants at study enrollment deﬁned as entry
time, and the age at the VTE event or censoring event (ie,
death, migration, or the date of study end) deﬁned as exit
time. Ischemic stroke was included as a time-dependent
covariate in the Cox model. Therefore, participants who
developed ischemic stroke during follow-up contributed with
person-years in both the unexposed and exposed group (ie,
unexposed person-years from baseline inclusion to stroke and
exposed person-years from stroke to end of follow-up). In
those who participated in several surveys, information on
potential confounders was updated at each survey. HRs for
VTE were estimated with 3 different models. The ﬁrst model
was adjusted for age (as time scale) and sex, while the second
model was additionally adjusted for BMI. Model 3 was
adjusted for age (as time scale), sex, BMI, diabetes mellitus,
smoking, systolic blood pressure, high-density lipoprotein
cholesterol, physical activity, and education. The proportional
hazard assumption was tested using Schoenfeld residuals and
found not violated. Statistical interactions between ischemic
stroke and sex were tested by including cross-product terms
in the proportional hazards models, and no interactions were
found. Finally, 1-Kaplan–Meier curves were estimated to
visualize the cumulative incidence of VTE over time in
subjects without and with incident ischemic stroke.
Results
During a median follow-up of 15.7 years, 1360 (4.5%)
subjects developed ischemic stroke and 722 (2.4%) subjects
developed VTE. Baseline characteristics of the study partic-
ipants are shown in Table 1. The mean age and BMI, as well
as the proportions of men and subjects with hypertension and
hypercholesterolemia were higher in stroke patients than in
those without stroke (Table 1).
Characteristics of the VTE events without and with
ischemic stroke with regard to anatomical localization and
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predisposing factors are shown in Table 2. In total, 57 of the
722 VTEs occurred in patients with an ischemic stroke. VTE
patients with an ischemic stroke had a higher proportion of
provoked events compared to those without stroke. More-
over, the proportion of patients that had been immobilized
before the VTE event was substantially higher in those with
stroke (51% versus 15%).
IR and HR for VTE among participants without and with
incident ischemic stroke during follow-up are shown in
Table 3. In participants without stroke, 665 VTE-events were
identiﬁed during 361 634 person-years of follow-up, corre-
sponding to IR of 1.8 per 1000 person-years. In subjects with
incident ischemic stroke, there were 57 VTEs identiﬁed during
6482 person-years of follow-up equivalent to IR of 10.3 per
1000 person-years. Ischemic stroke was associated with a 3-
times (HR 3.2; 95% CI 2.4–4.4) higher risk of VTE compared to
those without ischemic stroke. The IR of VTE was highest
during the ﬁrst month after an ischemic stroke (IR 82.1 per
1000 person-years) with a 20-fold higher risk (HR 19.7; 95%
CI, 10.1–38.5) compared to those without ischemic stroke. In
the period from 1 to 3 months after the stroke, the risk of VTE
was 11-fold increased in stroke patients (HR 10.6; 95% CI
5.0–22.5). The risk declined rapidly thereafter, and was in the
period more than 3 months only 1.5 times increased (HR 1.5;
95% CI, 1.1–2.2). Separate analyses of DVT and PE showed
that the risk of both outcomes was highest during the ﬁrst
3 months after the incident ischemic stroke (Table 3). The
multivariable HRs were 19.1 (95% CI, 7.8–46.9) and 10.3 (95%
CI, 3.8–28.0) for DVT and 20.2 (95% CI, 7.4–55.1) and 11.0
(95% CI, 3.5–35.5) for PE during the ﬁrst month and in the
period 1 to 3 months after stroke, respectively. The risk
estimates for both DVT (HR 1.3; 95% CI, 0.8–2.3) and PE (HR
1.8; 95% CI, 1.0–3.0) were no longer signiﬁcant after the ﬁrst
3 months.
The cumulative incidences of VTE in subjects without and
with ischemic stroke are shown in Figure 2. There was a
notable increase in the cumulative incidence of VTE during the
initial 3 months following an incident stroke as displayed by
the substantially steeper slope in the incidence curve for
subjects with ischemic stroke compared to those without
ischemic stroke. The cumulative incidence of VTE was 15%
during the ﬁrst 3 months in subjects with ischemic stroke,
compared with 0.2% in the general population during the
same time period. The incidence curves for VTE remained
Table 1. Baseline Characteristics of Participants Without and
With Ischemic Stroke (n=30 002)
No Ischemic
Stroke (n=28 642)
Ischemic Stroke
(n=1360)
Age, y 4614 6313
Sex (male) 47.1 (13 497) 54.0 (734)
BMI, kg/m2 25.33.9 26.64.1
Total cholesterol, mmol/L 5.941.29 6.741.30
HDL cholesterol, mmol/L 1.490.41 1.470.42
Triglycerides, mmol/L 1.531.04 1.841.13
Systolic blood pressure, mm Hg 13320 15325
Diastolic blood pressure, mm Hg 7712 8714
Hypertension* 32.7 (9380) 72.6 (988)
Hypercholesterolemia† 31.8 (9110) 55.2 (752)
Smoking‡ 35.7 (10 247) 34.0 (463)
Physical activity§ 32.9 (9411) 19.5 (265)
Educationk 28.3 (8116) 14.6 (198)
Self-reported diabetes mellitus 1.6 (468) 6.0 (82)
The Tromsø Study 1994–2010. Values are % (n) or meanSD. BMI indicates body mass
index; HDL, high-density lipoprotein.
*Mean systolic/diastolic blood pressure ≥140/≥90 mm Hg, use of antihypertensives, or
self-reported hypertension.
†Total cholesterol ≥6.5 mmol/L, use of lipid-lowering drugs, or self-reported
hypercholesterolemia.
‡Self-reported daily smoking, yes/no.
§≥1 hours of moderate or hard physical activity per week, yes/no.
k>10 years of education.
Table 2. Characteristics of VTE Events (n=722)
No Ischemic
Stroke (n=665)
% (n)
Ischemic
Stroke (n=57)
% (n)
Clinical characteristics
Deep vein thrombosis 58.0 (386) 50.9 (29)
Pulmonary embolism 42.0 (279) 49.1 (28)
Provoked 50.0 (332) 63.2 (36)
Unprovoked 50.0 (333) 36.8 (21)
Clinical risk factors
Estrogen*† 5.7 (38) 5.2 (3)
Pregnancy/puerperium* 0.9 (6) —
Heredity‡ 3.6 (24) —
Provoking factors
Surgery 15.9 (106) 7.0 (4)
Trauma 7.8 (52) 8.8 (5)
Cancer 24.5 (163) 17.5 (10)
Immobility§ 16.1 (107) 43.9 (25)
Other|| 5.3 (35) 1.8 (1)
The Tromsø Study 1994–2010. DVT indicates deep vein thrombosis; PE, pulmonary
embolism; VTE, venous thromboembolism.
*Only women included in the analysis.
†Current or previous use of hormone replacement therapy or oral contraceptives.
‡Venous thromboembolism in a ﬁrst-degree relative before 60 years of age.
§Bed rest >3 days, journeys of >4 hours by car, boat, train, or air within the last 14 days,
or other types of immobilization.
||Other provoking factor described by a physician in the medical record (eg, intravascular
catheter).
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essentially parallel in the period more than 6 months after the
incident ischemic stroke event (Figure 2).
In analyses stratiﬁed for the presence of provoking factors,
ischemic stroke displayed a higher risk for provoked VTE (HR
22.6; 95% CI, 12.5–40.9) than for unprovoked VTE (HR 7.4;
95% CI, 2.7–20.1) during the ﬁrst 3 months (Table 4). In
subgroup analyses, ischemic stroke was associated with a 20-
fold (HR 19.7; 95% CI, 9.1–42.7) higher risk of provoked DVT
and a 29-fold (HR 29.0; 95% CI, 11.5–73.6) higher risk of
provoked PE compared with subjects without ischemic stroke
(Table 4). The risk estimates for provoked VTE (HR 1.9; 95%
CI, 1.1–3.0), and provoked PE (HR 2.8; 95% CI, 1.3–5.7)
remained signiﬁcantly increased more than 3 months after
ischemic stroke, whereas the risk estimate for provoked DVT
was no longer statistically signiﬁcant (HR 1.4; 95% CI, 0.7–
2.8).
Discussion
In our prospective cohort study, subjects who developed
ischemic stroke had an increased risk of VTE, compared to
those without ischemic stroke in the general population. The
incidence rate and relative risk were especially high during the
ﬁrst 3 months after ischemic stroke and declined rapidly
thereafter. Analyses stratiﬁed on predisposing factors of VTE
displayed higher risk of provoked than unprovoked events,
although the conﬁdence intervals for the point estimates
overlapped. As stroke was associated with a transient
increased risk of both unprovoked and provoked VTE, our
ﬁndings suggest that mechanisms or conditions related to the
ischemic stroke itself contribute substantially to the associ-
ation between ischemic stroke and VTE.
Table 3. Incidence Rates and Hazard Ratios for VTE, DVT, and PE According to Ischemic Stroke Exposure
Person-Years VTE Events
Crude
IR (95% CI)*
Model 1†
HR (95% CI)
Model 2‡
HR (95% CI)
Model 3§
HR (95% CI)
Total VTE
No stroke 361 634 665 1.8 (1.7–2.0) Reference Reference Reference
<1 month 122 10 82.1 (44.2–152.5) 16.4 (8.7–30.8) 15.8 (8.4–29.8) 19.7 (10.1–38.5)
1 to 3 months 172 8 46.5 (23.2–92.9) 9.5 (4.7–19.2) 9.2 (4.5–18.5) 10.6 (5.0–22.5)
>3 months 5193 39 7.5 (5.5–10.3) 1.5 (1.1–2.1) 1.4 (1.0–2.0) 1.5 (1.1–2.2)
DVT
No stroke 361 634 386 1.1 (1.0–1.2) Reference Reference Reference
<1 month 122 6 49.2 (22.1–109.6) 17.7 (7.8–39.9) 17.4 (7.7–39.2) 19.1 (7.8–46.9)
1 to 3 months 172 4 23.2 (8.7–61.9) 8.7 (3.2–23.4) 8.5 (3.1–22.9) 10.3 (3.8–28.0)
>3 months 5193 19 3.7 (2.3–5.7) 1.3 (0.8–2.1) 1.2 (0.8–2.0) 1.3 (0.8–2.3)
PE
No stroke 361 634 279 0.8 (0.7–0.9) Reference Reference Reference
<1 month 122 4 32.8 (12.3–87.5) 14.8 (5.5–40.0) 14.0 (5.2–37.0) 20.2 (7.4–55.1)
1 to 3 months 172 4 23.2 (8.7–61.9) 10.4 (3.9–28.3) 10.0 (3.7–27.1) 11.2 (3.5–35.5)
>3 months 5193 20 3.9 (2.5–6.0) 1.7 (1.1–2.7) 1.6 (1.0–2.5) 1.8 (1.0–3.0)
The Tromsø Study 1994–2010. DVT indicates deep vein thrombosis; HR, hazard ratio; IR, incidence rates; PE, pulmonary embolism; VTE, venous thromboembolism.
*Per 1000 persons-years.
†Model 1: Age as timescale, adjusted for sex.
‡Model 2: Model 1+body mass index.
§Model 3: Model 2+systolic blood pressure, diabetes mellitus, high-density lipoprotein cholesterol, smoking, physical activity, and education level.
Figure 2. Overall cumulative incidence of venous thromboem-
bolism (VTE) in subjects with and without ischemic stroke. The
Tromsø Study 1994–2010.
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Comprehensive data from clinical trials of stroke patients
have consistently shown that stroke patients are at high risk
of VTE, and DVT in particular.5,6 However, only 1 previous
large registry-based case–control study conducted in Den-
mark has investigated the risk of VTE in stroke patients
compared to the general population.18 Stroke patients had an
overall 1.3-fold increased risk of VTE, but the risk was
particularly high during the ﬁrst 3 months after stroke with a
4.4-fold increased VTE risk compared to those without stroke.
Accordingly, we found that patients with ischemic stroke had
an overall 3-times higher risk of VTE compared with partic-
ipants without stroke. The risk was particularly high during the
ﬁrst month and the subsequent 2 months with a 20- and 11-
fold higher risk of VTE, respectively, and declined rapidly
thereafter. The explanations for the observed association
between ischemic stroke and future risk of VTE are yet
unknown, but may include shared risk factors, indirect factors,
or a direct relationship.22
Several lines of evidence argue against shared risk factors
explaining the association between ischemic stroke and VTE.
First, shared risk factors are expected to induce a permanent,
and not a transient VTE risk as observed in our study. Second,
adjustments for potentially shared cardiovascular risk factors
would presumably attenuate the VTE risk by ischemic stroke.
In our study, adjustments for cardiovascular risk factors had
marginal impact on the risk estimates for the association
between ischemic stroke and VTE. Third, ischemic stroke and
VTE patients did not share the same risk proﬁle. Cause-
Table 4. Incidence Rates and Hazard Ratios for VTE, DVT, and PE According to Ischemic Stroke Exposure by the Presence of
Predisposing Factors
Person-Years VTE Events
Crude
IR (95% CI)*
Model 1†
HR (95% CI)
Model 2‡
HR (95% CI)
Model 3§
HR (95% CI)
Provoked VTE
No stroke 361 634 332 0.9 (0.8–1.0) Reference Reference Reference
<3 months 294 14 47.6 (28.2–80.4) 19.3 (11.2–33.2) 18.8 (10.9–32.4) 22.6 (12.5–40.9)
>3 months 5193 22 4.2 (2.8–6.4) 1.1 (1.1–2.6) 1.5 (1.0–2.4) 1.9 (1.1–3.0)
Unprovoked VTE
No stroke 361 634 333 0.9 (0.8–1.0) Reference Reference Reference
<3 months 294 4 13.6 (5.1–36.2) 5.5 (2.0–14.8) 5.3 (1.9–14.2) 7.4 (2.7–20.1)
>3 months 5193 17 3.3 (2.0–5.3) 1.3 (0.8–2.2) 1.3 (0.8–2.1) 1.4 (0.8–2.5)
Provoked DVT
No stroke 361 634 216 0.6 (0.5–0.7) Reference Reference Reference
<3 months 294 8 27.2 (13.6–54.4) 17.5 (8.5–35.8) 17.2 (8.4–35.2) 19.7 (9.1–42.7)
>3 months 5193 12 2.3 (1.3–4.1) 1.4 (0.8–2.6) 1.3 (0.7–2.4) 1.4 (0.7–2.8)
Unprovoked DVT
No stroke 361 634 170 0.5 (0.4–0.5) Reference Reference Reference
<3 months 294 2 6.8 (1.7–27.2) 5.9 (1.4–23.8) 5.8 (1.4–23.4) 7.2 (1.8–29.6)
>3 months 5193 7 1.3 (0.6–2.8) 1.2 (0.5–2.5) 1.1 (0.5–2.5) 1.3 (0.6–3.0)
Provoked PE
No stroke 361 634 116 0.3 (0.3–0.4) Reference Reference Reference
<3 months 294 6 20.4 (9.2–45.4) 22.4 (9.7–51.8) 21.8 (9.4–50.1) 29.0 (11.5–73.6)
>3 months 5193 10 1.9 (1.0–3.6) 2.0 (1.0–3.9) 1.9 (1.0–3.7) 2.8 (1.3–5.7)
Unprovoked PE
No stroke 361 634 163 0.5 (0.4–0.5) Reference Reference Reference
<3 months 294 2 6.8 (1.7–27.2) 5.2 (1.3–21.0) 4.8 (1.2–19.7) 7.7 (1.9–31.5)
>3 months 5193 10 1.9 (1.0–3.6) 1.4 (0.7–2.8) 1.3 (0.7–2.6) 1.6 (0.7–3.4)
The Tromsø Study 1994–2010. DVT indicates deep vein thrombosis; HR, hazard ratio; IR, incidence rate; PE, pulmonary embolism; VTE, venous thromboembolism.
*Per 1000 persons-years.
†Model 1: Age as timescale, adjusted for sex.
‡Model 2: Model 1+body mass index.
§Model 3: Model 2+systolic blood pressure, diabetes mellitus, high-density lipoprotein cholesterol, smoking, physical activity, and education level.
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speciﬁc analyses of cardiovascular risk factors in the Physi-
cian’s Health Study revealed that only age and obesity were
shared risk factors for ischemic stroke and VTE.11 Our
ﬁndings do not exclude, however, the possibility of joint
effects between shared environmental23–25 and inherited26
prothrombotic risk factors that would augment the VTE risk
under conditions of high thrombosis risk related to the
ischemic stroke itself (eg, hospitalization, immobilization, and
secondary acute infections).2,16,17
Several ﬁndings from our study support the concept that
mechanism(s) or conditions related to the ischemic stroke
itself partly explain the association between stroke and VTE.
First, we observed a transient and short-term risk of VTE after
ischemic stroke. Patients with ischemic stroke are hospital-
ized and medical complications occur frequently (eg, respira-
tory- and urinary tract infections).2,16,17 These medical
complications may contribute to the increased VTE risk either
by themselves or via prolongation of the hospital stay.13
Second, stratiﬁed analyses displayed a higher risk of provoked
than unprovoked VTE by ischemic stroke, with a particular
preponderance of immobilization and acute medical condi-
tions as predisposing factors for VTE among patients with
ischemic stroke. Similarly, data from the Worcester VTE study
displayed a higher frequency of comorbid conditions and
immobilization in patients with stroke-related VTE compared
to VTE patients without stroke.27 Patients with ischemic
stroke are often temporarily immobilized due to bed-rest or
neurological deﬁcits of affected limbs, and are therefore more
susceptible for thrombus formation secondary to venous
stasis.28 Activation of the coagulation system during the
acute phase of ischemic stroke or secondary to medical
complications may also contribute to the VTE risk.29,30
Therefore, our ﬁndings suggest that transient indirect risk
factors, occurring in relation to the ischemic stroke, possibly
together with enhanced activity in the coagulation system, are
important contributors to the transient risk of VTE after
ischemic stroke.
For prevention of VTE, current guidelines recommend
initiation of subcutaneous anticoagulation with low-molecular-
weight heparin or unfractionated heparin within 48 hours
after ischemic stroke with duration of treatment throughout
the hospital stay or until the patient regains mobility.31
Unfortunately, we do not have information on the use of
preventive anticoagulant treatment during the rather long
study period (1995–2010). However, it is likely that the risk
estimates in our study are an underestimation of the real VTE
risk (ie, risk in the absence of thromboprophylaxis), as a
proportion of the stroke patients presumably have received
thromboprophylaxis. Despite this potential underestimation of
the VTE risk in stroke patients, we observed an absolute risk
increase of 48.1 per 1000 patients for DVT and 32.0 for PE
during the ﬁrst month after the ischemic stroke (compared to
subjects without ischemic stroke). Although some of the
preventive effect may already be incorporated in our results, a
recent meta-analysis of randomized clinical trials implies that
preventive treatment with low-molecular-weight heparin or
unfractionated heparin had the potential to reduce the
incidence of symptomatic DVT by 70% and the incidence of
fatal and nonfatal PE by 30%.31 On the other hand, improved
awareness and adherence to current guidelines for medical
thromboprophylaxis in stroke patients may have lowered VTE
rates during the last years.
Major strengths of our study include the prospective
design, the large number of participants recruited from a
general population, the long-term follow-up, the wide age
distribution, and validated events of ischemic stroke and VTE.
As many cardiovascular risk factors are modiﬁable, the
participants’ individual risk proﬁle may change during follow-
up, leading to regression dilution bias and potentially under-
estimation of the associations. However, an advantage of our
study is the repeated measurements of subject characteris-
tics during follow-up. Because of this, we may to a greater
extent account for changes in risk factor and confounders
during follow-up, resulting in more reliable risk estimates than
in a traditional cohort study. Still, some potential limitations
merit attention. In a cohort study, some groups are less likely
to participate and nonresponse bias is therefore possible. Our
estimated incidences of stroke and VTE may therefore be
lower than the true incidences. Furthermore, the low number
of both exposure and outcome events limits the statistical
power in subgroup analyses.
In our large cohort of subjects recruited from the general
population, subjects who developed ischemic stroke had a
transiently increased risk of VTE that was independent of
traditional cardiovascular risk factors. The transient nature of
the VTE risk following an ischemic stroke implies that
conditions related to the stroke itself, rather than shared risk
factors, are the main contributors to the VTE risk.
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